CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Cannabidiol (CBD)drug
Likely dose
Cannabidiol (CBD) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04754399
NCT04754399Phase 2Completed
CompareCT.gov

Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

University of Michigan Rogel Cancer Center·interventional·Posted Feb 15, 2021·Updated May 9, 2025

In Brief

A Phase 2 clinical trial evaluating Cannabidiol (CBD) for Arthralgia and Breast Cancer. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are looking to see if patients with joint pain see improvement with the use of CBD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthralgia, Breast Cancer
CountriesUnited States
CollaboratorsAmerican Society of Clinical Oncology

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 15, 2021
Enrollment StartApr 16, 2021
Primary CompletionOct 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.4 years ago

Interventions

Cannabidiol (CBD)drug

week 1: 25 mg twice daily, approximately 12 hours apart, with food week 2: 50 mg twice daily, approximately 12 hours apart, with food week 3: 75 mg twice daily, approximately 12 hours apart, with food week 4+: 100 mg twice daily, approximately 12 hours apart, with food